LANZMANN'S THROMBASTHENIA is a well-G defined inherited disorder of platelet
function.'.” It is caused by a deficiency or abnormality of the membrane glycoprotein (GP) IIb …

Platelets have a key role in atherosclerosis, thrombosis, and acute coronary syndromes.
Therapeutic manipulation of platelet function has focused principally on the use of aspirin …

Starting 90 years ago with a clinical description by Glanzmann of a bleeding disorder
associated with a defect in platelet function, technologic advances helped investigators …

From the initial description of platelets in 1882, their propensity to aggregate and to
contribute to thrombosis was apparent. Indeed, excessive platelet aggregation is associated …

Background—The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa
antagonist necessary to minimize thrombotic complications in patients undergoing a …

BACKGROUND Thrombosis has been implicated as central to the clinical complications of
coronary angioplasty (PTCA). Chimeric monoclonal 7E3 Fab (c7E3 Fab) is the first of a new …

FIBRINOLYTIC therapy is a major advance in the treatment of occlusive vascular disease.
Problems remain, however, including resistance to fibrinolytic therapy, delays in reperfusion …

Background Platelet activation and aggregation may be key components of thrombolytic
failure to restore and maintain perfusion in acute myocardial infarction. We performed a …

Moving from bench to bedside in the development of the monoclonal antibody 7E3, directed
against the platelet GPIIb/IIIa receptor, from a basic science laboratory reagent to an …

This review discusses the advantages and disadvantages of currently available tests for the
monitoring of antiplatelet therapy (especially aspirin and clopidogrel). Many tests of platelet …